03/26/2026 13:00
Vena Completes Acterys Acquisition to Accelerate Orchestrated Planning for the Microsoft Ecosystem

Vena, the AI-powered Orchestrated Performance Management platform purpose-built to fully amplify the Microsoft technology ecosystem, today announced it has completed its acquisition of Acterys, the leading Microsoft Power BI–based operational planning and app development platform. The move strengthens Vena’s Orchestrated Planning solution and begins phased integration of the two platforms. Modern enterprises are struggling to keep up with the volatility and dynamism of the markets they serve....

ChatEurope launches live video coverage to bring EU news closer to citizens

ChatEurope, the go-to platform for European affairs created by leading European media outlets, enhances its offer with the launch of key EU events live video coverage.

ChatEurope, the go-to platform for European affairs created by leading European media outlets, enhances its offer with the launch of key EU events live video coverage.
03/29/2026 23:35
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”

Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/Conceptual Diagram of ...

04/01/2026 09:11
Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,” said Thomas Fuchs, CEO, Mosaic Therapeutics. “His deep expertise in tar...

04/01/2026 11:19
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending

Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking licens...

04/01/2026 09:40
Danube Properties Unveils AED 3.5M+ ‘Greenz’ Master Community in Dubai’s High-Growth Academic City

Danube Properties has unveiled Greenz By Danube, its first large-scale integrated community featuring premium townhouses and villas - marking a major milestone in its expansion into master-planned developments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401810554/en/Danube Properties Unveils AED 3.5M+ ‘Greenz’ Master Community in Dubai’s High-Growth Academic City (Photo: AETOSWire) Strategically located in Dubai International...

04/01/2026 11:30
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resi...